Research & Development

Anti-C5aR antibody shows promise as immuno-oncology treatment

12 November 2020 | By Victoria Rees (Drug Target Review)

Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.

Study suggests beta cell regeneration driven by circadian rhythms

12 November 2020 | By Victoria Rees (Drug Target Review)

Researchers have shown that the internal clock controls the regenerative mechanism behind beta cells in diabetic mice.

RNA structures of SARS-CoV-2 reveal potential drug targets

11 November 2020 | By Victoria Rees (Drug Target Review)

The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.

New bioprocess generates haematopoietic stem and progenitor cells

10 November 2020 | By Victoria Rees (Drug Target Review)

A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.

Researchers develop ACE2 decoy to neutralise SARS-CoV-2

10 November 2020 | By Hannah Balfour (Drug Target Review)

Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.

Novel antibody-drug candidate to treat pancreatic cancer developed

10 November 2020 | By Victoria Rees (Drug Target Review)

Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).

Pre-existing coronavirus antibodies could protect against new COVID-19 strains

9 November 2020 | By Victoria Rees (Drug Target Review)

Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.

Role of retrons in bacteria revealed, with potential for use in gene editing

9 November 2020 | By Victoria Rees (Drug Target Review)

The role that retrons in bacteria has been discovered by researchers, who found they protect colonies when infected by viruses.

Inflammatory bowel disease drugs could combat COVID-19, study suggests

6 November 2020 | By Victoria Rees (Drug Target Review)

Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.

Developing drugs for disordered proteins

6 November 2020 | By Hannah Balfour (Drug Target Review)

Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.

Team identifies new potential approach to treat multiple sclerosis

6 November 2020 | By Victoria Rees (Drug Target Review)

Researchers have prevented immune cells from attacking myelin in mice, which stopped the progression of multiple sclerosis (MS).

Protease inhibitor aprotinin shows promise against SARS-CoV-2 in cells

5 November 2020 | By Victoria Rees (Drug Target Review)

Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.

Persistence of infected cells in lungs could explain long-term COVID-19 symptoms, say scientists

4 November 2020 | By Victoria Rees (Drug Target Review)

Researchers have found the genome of COVID-19 and infected cell syncytia in the respiratory cells of deceased patients, potentially explaining long-term coronavirus effects.

IDBS

Scientists identify new way to target leukaemia cells

28 October 2020 | By Victoria Rees (Drug Target Review)

Researchers have found they can make leukaemia cells vulnerable by dislodging leukaemia stem cells from a tumour-promoting niche.